On April 26, Otsuka Pharmaceuticals Co. Ltd. filed a patent infringement suit against Amneal Pharmaceuticals LLC, arguing that Amneal and two of its affiliates, “had infringed Otsuka’s patent by submitting an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA).” The complaint stated that “Amneal has infringed at least one claim of the ‘257 patent by submitting, or causing to be submitted to the FDA, ANDA No. 20-3906 seeking approval for the commercial marketing of Amneal’s generic before the expiration date of the ‘257 patent. Amneal’s generic product will, if approved and marketed, infringe at least one claim of the ‘257 patent.” Otsuka is represented by Finnegan in this matter.
